Terran Biosciences
↗Miami Beach, Florida, USA
Terran Biosciences is a biotech platform company devoted to the development of transformative therapeutics and technologies for patients with neurological and psychiatric diseases. Founded in 2017 by Dr. Samuel Clark, the company has assembled a robust portfolio through strategic acquisitions and partnerships, including assets from Concert Pharmaceuticals, Sanofi, and Pierre Fabre. The company operates across three major areas: novel drug development for schizophrenia and CNS disorders, psychedelic-based therapeutics with one of the largest industry pipelines, and AI-enabled diagnostic imaging technology. Terran's platform approach combines medicinal chemistry innovation (including novel prodrug formulations) with intellectual property strategy focused on next-generation formulations of existing compounds.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:-
Industry:Biotechnology
Sub-Industry:Therapeutic biotech (CNS/Neuropsychiatry)
SIZE & FINANCIALS
Employees:51-200
Founded:2017
Ownership:private
Status:operating
FUNDING
Stage:Growth/Late Stage
Total Raised:$113M
Investors:Magna Filis, Astir Ventures, Catalytic Impact Foundation, Brkfst Club, Manta Capital Advisors, Magnetic Ventures, Bruker, Noetic Fund, Victor Douce
PIPELINE
Stage:Phase 1|Phase 2|Phase 3|Commercial (NM-101 FDA cleared)
Lead Drug Stage:Phase 1 (TerXT - oral formulation planned; Idazoxan XR - Phase 1)
Modalities:Small molecule, Novel prodrugs, Deuterated compounds, Psychedelic compounds, Diagnostic software (AI-enabled imaging)
Active Trials:100
Trial Phases:Phase 1: 2 | Phase 3: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Pierre Fabre: Exclusive worldwide licensing rights for idazoxan portfolio and related compounds; idazoxan tested in 1000+ patients across Phase 3 studies, Sanofi: Exclusive worldwide licensing rights for two late-stage CNS pipeline assets; generated 4 INDs and 104 clinical studies with 15,000+ subjects, Concert Pharmaceuticals: Acquisition of deuterated CNS therapeutic compounds portfolio, University of Maryland, Baltimore: Exclusive licensing agreement for psychedelic therapeutic patents and research data
COMPETITION
Position:Challenger
Competitors:COMPASS Pathways, Neurosterix, Neumora, MapLight, GH Research, Gene Solutions, KeifeRx, Suven Neurosciences +2 more
LEADERSHIP
Key Executives:
Samuel Clark, MD, PhD - Founder & CEO
Dustin Tetzl, MD - Chief Business Officer
David Pickar - Chief Scientific Officer
Marine Yamada - Senior Manager, Strategy & Operations
Kazi Tasnim - Manager, Strategy & Operations
Scientific Founders:Samuel Clark, MD, PhD
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Terran Biosciences. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.